14 Results

People

  1. Horwitz
    Horwitz
  2. Usmani
    Usmani
  3. Buege
    Buege
  4. Dao
    Dao
  5. Drill
    Drill
  6. Giralt
    Giralt
  7. Goldberg
    Goldberg
  8. Landau
    Landau
  9. Landgren
    Landgren
  10. Levoir
    Levoir

Groups

  1. Hematologic Malignancies, Division of (12)
  2. Center for Hematologic Malignancies (11)
  3. Department of Medicine (11)
  4. Lymphoma (5)
  5. Population Sciences Research Program (4)
  6. Adult Leukemia (3)
  7. Bone Marrow Transplant (3)
  8. Clinical Pharmacy Specialists (1)
  9. Epidemiology and Biostatistics (1)
  10. Genitourinary Oncology Service (1)
  1. "retrospective study"
  2. "Clinical Lymphoma, Myeloma and Leukemia"
Formats
  1. Journal Article (14)
Groups
  1. Hematologic Malignancies, Division of (12)
  2. Center for Hematologic Malignancies (11)
  3. Department of Medicine (11)
  4. Lymphoma (5)
  5. Population Sciences Research Program (4)
  6. Adult Leukemia (3)

More Groups

People
  1. Steven Horwitz (4)
  2. Anthony Mato (2)
  3. Saad Usmani (2)
  4. Andrea Levoir (1)
  5. Andrew Zelenetz (1)
  6. Carl Landgren (1)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (14)
Publishers
  1. Elsevier Inc. (14)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study
    Journal Article

    Gordan, L. N.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Mato, A. R.; Hess, L. M.; Chen, Y.; Abada, P. B.; Konig, H.; Pagel, J. M.; Walgren, R. A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Characteristics and outcome of extranodal NK/T-cell lymphoma in North America: A retrospective multi-institutional experience
    Journal Article

    Bennani, N. N.; Tun, A. M.; Carson, K. R.; Geiger, J. L.; Maeda, L. S.; Savage, K. J.; Rose, J.; Pinter-Brown, L.; Lunning, M. A.; Abramson, J. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Characteristics and outcome of extranodal NK/T-cell lymphoma in North America: A retrospective multi-institutional experience
    Journal Article

    Bennani, N. N.; Tun, A. M.; Carson, K. R.; Geiger, J. L.; Maeda, L. S.; Savage, K. J.; Rose, J.; Pinter-Brown, L.; Lunning, M. A.; Abramson, J. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Real-world outcomes of ruxolitinib treatment for polycythemia vera
    Journal Article

    Coltoff, A.; Mesa, R.; Gotlib, J.; Shulman, J.; Rampal, R. K.; Siwoski, O.; Yacoub, A.; Moliterno, A.; Yang, A.; Braunstein, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy
    Journal Article

    Emond, B.; Sundaram, M.; Romdhani, H.; Lefebvre, P.; Wang, S.; Mato, A.
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Immune signatures associated with clonal isotype switch after autologous stem cell transplantation for multiple myeloma
    Journal Article

    Ye, R.; Kundrapu, S.; Gerson, S. L.; Driscoll, J. J.; Beck, R.; Ali, N.; Landgren, O.; VanHeeckeren, W.; Luo, G.; Kroger, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p
    Journal Article

    Wong, S. W.; Hegenbart, U.; Palladini, G.; Shah, G. L.; Landau, H. J.; Warner, M.; Toskic, D.; Jaccard, A.; Hansen, T.; BladeĢ, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save